Press release distribution, EDGAR filing, XBRL, regulatory filings
Fitch has also downgraded the issue ratings ... )--Humacyte, Inc., a pioneer in regenerative medicine, has announced that the U.S. Food and Drug Administration has designated the HumaGrafta devel... )--FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of ... (more)
Clean Harbors to Announce Second-Quarter 2014 Financial Results on August 6
On the call, Chairman and Chief Executive Officer Alan S. McKim and Vice Chairman, President and Chief Financial Officer James M. Rutledge will discuss Clean Harbors' financial results, business outlook and growth strategy.
Wedbush Increases Clean Harbors Price Target to $60.00
The firm currently has a "neutral" rating on the stock. Wedbush's price target indicates a potential downside of 1.22% from the stock's previous close.
Clean Harbors Director John F. Kaslow Sells 1,534 Shares
Clean Harbors Director John F. Kaslow sold 1,534 shares of Clean Harbors stock in a transaction dated Monday, June 23rd.